PharmiWeb.com - Global Pharma News & Resources
04-Feb-2019

Cedilla Therapeutics Expands Leadership Team with Appointment of Chief Human Resources Officer

Cedilla Therapeutics, a biotechnology company broadening the reach of small molecule therapeutics by discovering and exploiting unique insights into protein stability, today announced the appointment of a veteran biopharma executive, Andrew Dawson, as chief human resources officer. Dawson brings a wealth of experience in company growth and culture development, as well as talent acquisition and coaching.

“We’re delighted to welcome Andrew to Cedilla as we continue to build out our team and expand our capabilities in drug discovery and development,” said Alexandra Glucksmann, Cedilla’s president and chief executive officer. “He will play an integral role on our leadership team.”

Dawson brings more than 20 years of global experience in human resources across the biotech and pharmaceutical industries. He joins Cedilla after having served in senior roles of increasing scope and responsibility at Shire, Roche, Novartis, Eli Lilly and TripAdvisor. Most recently, he was a senior vice president and head of human resources at Enzyvant, leading the worldwide human resources function and serving as a member of the executive leadership team. Dawson received his M.Sc. in human resources management and development from the University of Salford in Manchester, England.

“It’s a joy to step into this role in a startup with such a welcoming and supportive culture – and such a strong sense of mission to deliver new classes of drugs to patients,” Dawson said. “I look forward to helping guide Cedilla’s growth.”

About Cedilla Therapeutics

Cedilla Therapeutics is discovering and exploiting unique insights into protein stability. Cedilla’s integrated, multi-faceted approach has the potential to broaden the reach of small molecules by generating therapeutics that degrade protein targets as their primary mechanism of action. The approach harnesses intrinsic degradation pathways that are upstream of ubiquitination. Cedilla is focused on destabilizing oncoprotein targets using a product engine that is also applicable to targets outside of oncology. Cedilla was launched in 2018 by Third Rock Ventures and is based in Cambridge, Mass. For more information, please visit www.cedillatx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190204005081/en/

Editor Details

Last Updated: 04-Feb-2019